Roche Aktie

306,10 EUR +1,75 EUR +0,58 %

11:27:57

FSE

284,70 CHF +0,60 CHF +0,21 %

12:32:56

SWX

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.245,54 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

08.12.23GlobeNewswireRoche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

05.12.23GlobeNewswireRoche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

04.12.23GlobeNewswireRoche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

27.11.23GlobeNewswireRoche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection

20.11.23PR NewswireRoche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges

16.11.23GlobeNewswireRoche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List

14.11.23GlobeNewswireRoche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types

09.11.23GlobeNewswireRoche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation

30.10.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functio

27.10.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

26.10.23PR NewswireRoche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses

23.10.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory

19.10.23MyDividendsRoche strebt Dividendenanhebung an

19.10.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

19.10.23GlobeNewswire[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum trotz Rückgang der Nachfrage nach COVID-19-Produkten

18.10.23GlobeNewswireRoche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns

18.10.23GlobeNewswireRoche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer

13.10.23GlobeNewswireLate-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis

12.10.23GlobeNewswireNew data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided

11.10.23GlobeNewswireRoche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions

10.10.23GlobeNewswireRoche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

04.10.23GlobeNewswireMajority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment

02.10.23GlobeNewswireRoche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

07.09.23GlobeNewswireRoche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardi

05.09.23PR NewswireEconomist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare

01.09.23GlobeNewswireRoche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

29.08.23GlobeNewswireRoche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes

29.08.23GlobeNewswireEuropean Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)

23.08.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

17.08.23PR NewswireRoche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency

08.08.23PR NewswireNew opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services

03.08.23PR NewswireRoche expands long-term alliance with Sysmex

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.